Catechol diethers as potent anti-HIV agents
The present invention is directed to novel catechol diether compounds, pharmaceutical compositions therefrom and methods for inhibiting reverse transcriptase and treating HIV infections, especially included drug resistant strains of HIV 1 and 2 and/or secondary disease states and/or conditions which occur as a consequence of HIV infection.
1. A compound according to the chemical structure:
wherein R 1 is H, OH, a halogen, CN, NO 2 , morpholinylethoxy, an optionally substituted alkyl group, an optionally substituted C 2 -C 6 alkene group, an optionally substituted C 2 -C 6 alkyne group, —(CH 2 ) m —NR A R B , —(CH 2 ) m —C(O)NR A R B1 , —(CH 2 ) m —NR A C(O)R C , —(CH 2 ) m —O—(C 1 -C 6 ) alkyl which is optionally substituted, —O—(CH 2 ) m —O—(C 1 -C 6 ) alkyl which is optionally substituted, —(CH 2 ) m —O—(CH 2 ) m —O—(C 1 -C 6 ) alkyl which is optionally substituted,
—(CH 2 ) m —C(O)—(C 1 -C 6 ) alkyl which is optionally substituted, —(CH 2 ) m —OC(O)—C 1 -C 6 alkyl which is optionally substituted, or —(CH 2 ) m —C(O)O—C 1 -C 6 alkyl which is optionally substituted;
R A and R B are each independently H or an optionally substituted C 1 -C 6 alkyl group;
R B1 is H, an optionally substituted C 1 -C 6 alkyl group or an optionally substituted —(CH 2 ) m —O—(C 1 -C 6 ) alkyl group;
R C is H, an optionally substituted C 1 -C 6 alkyl group, or an optionally substituted —(CH 2 ) m —O—(C 1 -C 6 ) alkyl group;
R′ is H, OH, a halogen, CN, NO 2 , an optionally substituted C 1 -C 6 alkyl group, —(CH 2 ) m —O—(C 1 -C 6 ) alkyl which is optionally substituted, —O—(CH 2 ) m —O—(C 1 -C 6 ) alkyl which is optionally substituted, —(CH 2 ) m —C(O)—(C 1 -C 6 ) alkyl which is optionally substituted, —(CH 2 ) m —OC(O)—C 1 -C 6 alkyl which is optionally substituted, or —(CH 2 ) m —C(O)O—C 1 -C 6 alkyl which is optionally substituted;
X′ and Y′ are each independently a bond (absent), O, S, S(O) (sulfoxide) or S(O)(O)(sulfone);
R 3 is H, OH, a C 1 -C 3 alkyl group which is optionally substituted with up to three halogens, —O—C 1 -C 3 alkyl, which is optionally substituted with up to three halogens, a halogen, NO 2 or CN;
j, j 1 , m, n and n 1 are each independently 0, 1, 2 or 3;
X and Y are each independently H, OH, a halogen, CN, NO 2 , an optionally substituted C 1 -C 6 alkyl group, an optionally substituted C 2 -C 6 alkene group, an optionally substituted C 2 -C 6 alkyne group, —(CH 2 ) m —NR A R B , —(CH 2 ) m —C(O)NR A R B1 , —(CH 2 ) m —NR A C(O)R C , —(CH 2 ) m —O—(C 1 -C 6 ) alkyl which is optionally substituted, —O—(CH 2 ) m —O—(C 1 -C 6 ) alkyl which is optionally substituted,
—(CH 2 ) m —C(O)—(C 1 -C 6 ) alkyl which is optionally substituted, —(CH 2 ) m —OC(O)—C 1 -C 6 alkyl which is optionally substituted, or —(CH 2 ) m —C(O)O—C 1 -C 6 alkyl which is optionally substituted, or X and Y, together with W, form an optionally substituted pyrrole ring, an optionally substituted dihydrofuran ring or an optionally substituted dihydropyrrole ring;
W is N or C, wherein when W is N, W, X and Y together form an optionally substituted five-membered pyrrole ring and when W is C, C is optionally substituted with X, Y or R 3 , or alternatively, W, X and Y form an optionally substituted dihydrofuran ring or an optionally substituted dihydropyrrole ring; and
R p is an optionally substituted C 1 -C 6 alkyl group or an optionally substituted 6 membered heteroaryl group, or
a pharmaceutically acceptable salt, enantiomer, stereoisomer, solvate or polymorph thereof.
2. The compound according to claim 1 wherein R 1 and is H, halogen, CN, NO 2 , NH 2 , NHCH 3 , or morpholinylethoxy.
3. The compound according to claim 1 wherein either of R 1 or R′ is H.
4. The compound according to claim 1 wherein R 1 and R′ are each independently H or a halogen.
5. The compound according to claim 4 wherein R 1 is Cl or F and R′ is H.
6. The compound according to claim 1 wherein X and Y are each independently H, halogen, CN, NO 2 , (E)-cyanovinyl, methoxyethoxy or 3-hydroxypropan-1-oxy.
7. The compound according to claim 1 wherein X′ and Y′ are both O, j, j 1 and n 1 are each 0 and n is 1 or 2.
8. The compound according to claim 1 wherein Rp is a pyrimidine group attached at the N-1 position of the pyrimidine group and contains a substituent R 2a , attached at the 5- or 6-position of the pyrimidine group, wherein the R 2a is H, CH 3 , F, Cl, Br or I.
9. The compound according to claim 1 wherein Rp is a uracil group attached at the N-1 position of the uracil group and contains a substituent R 2a , attached at the 5-position of the uracil group, wherein the R 2a is H or CH 3 .
10. The compound according to claim 1 wherein the compound is
11. A compound according to the chemical structure:
wherein W is N or C;
R 1 is H, OH, a halogen, a morpholinylethoxy group, an optionally substituted alkyl group, an optionally substituted C 2 -C 6 alkene group, an optionally substituted C 2 -C 6 alkyne group, —(CH 2 ) m —NR A R B , —(CH 2 ) m —C(O)NR A R B1 , —(CH 2 ) m —NR A C(O)R C , —(CH 2 ) m —O—(C 1 -C 6 ) alkyl which is optionally substituted, —O—(CH 2 ) m —O—(C 1 -C 6 ) alkyl which is optionally substituted, —(CH 2 ) m —O—(CH 2 ) m —O—(C 1 -C 6 ) alkyl which is optionally substituted, —(CH 2 ) m —C(O)—(C 1 -C 6 ) alkyl which is optionally substituted, —(CH 2 ) m —OC(O)—C 1 -C 6 alkyl which is optionally substituted, or —(CH 2 ) m —C(O)O—C 1 -C 6 alkyl which is optionally substituted;
R A and R B are each independently H or an optionally substituted C 1 -C 6 alkyl group;
R B1 is H, an optionally substituted C 1 -C 6 alkyl group, or an optionally substituted —(CH 2 ) m —O—(C 1 -C 6 ) alkyl group;
R C is H, an optionally substituted C 1 -C 6 alkyl group or an optionally substituted —(CH 2 ) m —O—(C 1 -C 6 ) alkyl group;
R′ is H, OH, a halogen, CN, NO 2 , an optionally substituted C 1 -C 6 alkyl group,
—(CH 2 ) m —O—(C 1 -C 6 ) alkyl which is optionally substituted, —O—(CH 2 ) m —O—(C 1 -C 6 ) alkyl which is optionally substituted, —(CH 2 ) m —C(O)—(C 1 -C 6 ) alkyl which is optionally substituted,
—(CH 2 ) m —OC(O)—C 1 -C 6 alkyl which is optionally substituted, or —(CH 2 ) m —C(O)O—C 1 -C 6 alkyl which is optionally substituted;
X′ and Y′ are each independently a bond (absent), O, S, S(O) (sulfoxide) or S(O)(O)(sulfone);
R 3 is H, OH, a C 1 -C 3 alkyl group which is optionally substituted with up to three halogens,
—O—C 1 -C 3 alkyl which is optionally substituted with up to three halogens, a halogen, NO 2 or CN;
j, j 1 , m, n and n 1 are each independently 0, 1, 2 or 3;
X 1 is
or N—R X when W is C, or
when W is N;
Z is
Y 1 is
O or N—R Y when W is C, or
when W is N;
R 2 is H, a C 1 -C 3 alkyl optionally substituted with up to three fluorines, CN or halogen; and
R X and R Y are each independently H or a C 1 -C 6 alkyl (or a C 1 -C 3 alkyl) group, optionally substituted with one or two hydroxyl groups, and
R p is an optionally substituted 5- or 6-membered heterocyclic group, or
a pharmaceutically acceptable salt, enantiomer, stereoisomer, solvate or polymorph thereof.
12. The compound according to claim 11 wherein R 1 is H, halogen, CN, NO 2 , NH 2 , NHCH 3 , or a morpholinylethoxy group.
13. The compound according to claim 11 wherein R 1 and R′ are each independently H or a halogen.
14. The compound according to claim 13 wherein R 1 is Cl or F and R′ is H.
15. The compound according to claim 11 wherein R 3 is H, a halogen or CN.
16. The compound according to claim 11 wherein X′ and Y′ are both O, j, j 1 and n 1 are each 0 and n is 1 or 2.
17. The compound according to claim 11 wherein Rp is a pyrimidine attached at the N-1 position and contains substituent R 2a , attached at the 5-position of the pyrimidine wherein the R 2a is H, CH 3 , F or Cl.
18. The compound according to claim 11 wherein Rp is a uracil group attached at the N-1 position and contains a substituted R 2a , attached at the 5-position of the uracil group, wherein the R 2a is H or CH 3 .
19. The compound according to claim 11 wherein the compound according to the chemical structure:
wherein R 1 is H, a halogen, CN, NO 2 , or an optionally substituted alkyl group;
Each R 2 is independently H, a C 1 -C 3 alkyl optionally substituted with up to three fluorines, CN or a halogen;
R 3 is H, OH, a C 1 -C 3 alkyl group which is optionally substituted with up to 3 halogens, a halogen, NO 2 or CN;
Rp is an optionally substituted pyrimidine linked at the 1-position of the pyrimidine optionally substituted at the 5- or 6-position with a substituent R 2a ;
R 2a is H, halogen, optionally substituted C 1 -C 3 alkyl, optionally substituted —O—(C 1 -C 3 ) alkyl or CN;
W is N or C;
X 1 is
O or N—R X when W is C, or
when W is N;
Z is
Y 1 is
O or N—R Y when W is C, or
when W is N; and
R X and R Y are each independently H or a C 1 -C 6 alkyl group, optionally substituted with one or two hydroxyl groups;
or a pharmaceutically acceptable salt, solvate or polymorph thereof.
20. The compound according to claim 19 wherein R 2a is H.
21. The compound according to claim 19 wherein R 1 is H, a halogen or a CN group.
22. The compound according to claim 19 wherein R 3 is H, a halogen or CN.
23. The compound according to claim 19 wherein R p is a uracil group.
24. The compound according to claim 19 wherein R p is a uracil group and R 2a is H, a halogen or CH 3 .
25. The compound according to claim 19 wherein W is N.
26. The compound according to claim 19 wherein W is C.
27. The compound according to claim 19 wherein the compound is
28. A pharmaceutical composition comprising an effective amount of a compound according to claim 1 or claim 11 in combination with a pharmaceutically acceptable carrier, additive or excipient.
29. The composition according to claim 28 wherein said compound is combined with another anti-HIV agent.
30. The composition according to claim 29 wherein said anti-HIV agent is selected from the group consisting of nucleoside reverse transcriptase inhibitors (NRTI), other non-nucleoside reverse transcriptase inhibitors, protease inhibitors, fusion inhibitors and mixtures thereof.
31. The composition according to claim 29 wherein said another anti-HIV agent is selected from the group consisting of 3TC (Lamivudine), AZT (Zidovudine), (−)-FTC, ddI (Didanosine), ddC (zalcitabine), abacavir (ABC), tenofovir (PMPA), D-D4FC (Reverset), D4T (Stavudine), Racivir, L-FddC, L-FD4C (Elvucitabine), NVP (Nevirapine), DLV (Delavirdine), EFV (Efavirenz), SQVM (Saquinavir mesylate), RTV (Ritonavir), IDV (Indinavir), SQV (Saquinavir), NFV (Nelfinavir), APV (Amprenavir), LPV (Lopinavir), a fusion inhibitor and a mixture thereof.
32. The composition according to claim 29 wherein said another anti-HIV agent is nevirapine (BI-R6-587), delavirdine (U-90152S/T), efavirenz (DMP-266), UC-781 (N-[4-chloro-3-(3-methyl-2-butenyloxy)phenyl]-2methyl3-furancarbothiamide), etravirine (TMC125), Trovirdine (Ly300046.HCl), MKC-442 (emivirine, coactinon), HI-236, HI-240, HI-280, HI-281, rilpivirine (TMC-278), MSC-127, HBY 097, DMP266, Baicalin (TJN-151) ADAM-II (Methyl 3′,3′-dichloro-4′,4″-dimethoxy-5′,5″-bis(methoxycarbonyl)-6,6-diphenylhexenoate), Methyl 3-Bromo-5-(1-5-bromo-4-methoxy-3-(methoxycarbonyl)phenyl)hept-1-enyl)-2-methoxybenzoate 5 chloro-3-(phenylsulfinyl)-2′-indolecarboxamide, U-104489 (PNU-104489), Capravirine (AG-1549, S-1153), atevirdine (U-87201E), aurin tricarboxylic acid (SD-095345), 1-[(6-Cyano-2-indoylyl)carbonyl]-4-[3-(isopropylamino)-2-pyridinyl]piperazine, 1-[5-[[N-(methyl)methylsulfonylamino]-2-indolylcarbonyl-4-[3-(isopropylamino)-2-pyridinyl]piperazine, 1-[3-(Ethylamino)-2-[pyridinyl]-4-[(5-hydroxy-2-indolyl)carbonyl]piperazine, 1-[(6-Formyl-2-indoyly)carbonyl]-4-[3-(isopropylamino)-2-pyridinyl]piperazine, 1-[[5-(Methylsulfonyloxy)-2-indoyly)carbonyl]-4-[3-(isopropylamino)-2-pyridinyl]piperazine, U88204E, Bis(2-nitrophenyl)sulfone (NSC 633001), Calanolide A (NSC675451), Calanolide B, 6-Benzyl-5-methyl-2-(cyclohexyloxy)pyrimidin-4-one (DABO-546), DPC 961, E-EBU, E-EBU-dm, E-EPSeU, E-EPU, Foscarnet (Foscavir), HEPT (1-[(2-Hydroxyethoxy)methyl]-6-(phenylthio)thymine), HEPT-M (1-[(2-Hydroxyethoxy)methyl]-6-(3-methylphenyl)thio)thymine), HEPT-S(1-[(2-Hydroxyethoxy)methyl]-6-(phenylthio)-2-thiothymine), Inophyllum P, L-737,126, Michellamine A (NSC650898), Michellamine B (NSC649324), Michellamine F, 6-(3,5-Dimethylbenzyl)-1-[(2-hydroxyethoxy)methyl]-5-isopropyluracil, 6-(3,5-Dimethylbenzyl)-1-(ethyoxymethyl)-5-isopropyluracil, NPPS, E-BPTU (NSC 648400), Oltipraz (4-Methyl-5-(pyrazinyl)-3H-1,2-dithiole-3-thione), N-{2-(2-Chloro-6-fluorophenethyl]-N′-(2-thiazolyl)thiourea (PETT Cl, F derivative), N-{2-(2,6-Difluorophenethyl]-N′-[2-(5-bromopyridyl)]thiourea, N-{2-(2,6-Difluorophenethyl]-N′-[2-(5-methylpyridyl)]thiourea, N-[2-(3-Fluorofuranyl)ethyl]-N′-[2-(5-chloropyridyl)]thiourea, N-[2-(2-Fluoro-6-ethoxyphenethyl)]-N′-[2-(5-bromopyridyl)]thiourea, N-(2-Phenethyl)-N′-(2-thiazolyl)thiourea (LY-73497), L-697,639, L-697,593, L-697,661, 3-[2-(4,7-Difluorobenzoxazol-2-yl)ethyl}-5-ethyl-6-methyl(pypridin-2(1H)-thione, 3-[[(2-Methoxy-5,6-dimethyl-3-pyridyl)methyl]amine]-5-ethyl-6-methyl(pypridin-2(1H)-thione, R82150, R82913, R87232, R88703, R89439 (Loviride), R90385, S-2720, Suramin Sodium, TBZ (Thiazolobenzimidazole, NSC 625487), Thiazoloisoindol-5-one, (+)(R)-9b-(3,5-Dimethylphenyl-2,3-dihydrothiazolo[2,3-a]isoindol-5(9bH)-one, Tivirapine (R86183), UC-38, UC-84 or a mixture thereof.
33. The compound according to claim 19 wherein R 1 and R 3 are each F, W is N, R 2 is H or CN and Rp is an optionally substituted pyrimidine linked at the 1-position of the pyrimidine optionally substituted at the 5- or 6-position with a substituent R 2a wherein the R 2a is H, F or Cl.
34. The compound according to claim 33 wherein R 2 in X 1 is H, R 2 in Z is CN, R 2 in Y 1 is H and said pyrimidine is uracil.
35. A pharmaceutical composition comprising an effective amount of a compound according to claim 34 in combination with a pharmaceutically acceptable carrier, additive or excipient.
36. The composition according to claim 35 wherein said compound is combined with another anti-HIV agent.
37. The composition according to claim 36 wherein said anti-HIV agent is selected from the group consisting of nucleoside reverse transcriptase inhibitors (NRTI), other non-nucleoside reverse transcriptase inhibitors, protease inhibitors, fusion inhibitors and mixtures thereof.
38. The composition according to claim 36 wherein said another anti-HIV agent is selected from the group consisting of 3TC (Lamivudine), AZT (Zidovudine), (−)-FTC, ddI (Didanosine), ddC (zalcitabine), abacavir (ABC), tenofovir (PMPA), D-D4FC (Reverset), D4T (Stavudine), Racivir, L-FddC, L-FD4C (Elvucitabine), NVP (Nevirapine), DLV (Delavirdine), EFV (Efavirenz), SQVM (Saquinavir mesylate), RTV (Ritonavir), IDV (Indinavir), SQV (Saquinavir), NFV (Nelfinavir), APV (Amprenavir), LPV (Lopinavir), a fusion inhibitor and a mixture thereof.
39. The composition according to claim 36 wherein said another anti-HIV agent is nevirapine (BI-R6-587), delavirdine (U-90152S/T), efavirenz (DMP-266), UC-781 (N-[4-chloro-3-(3-methyl-2-butenyloxy)phenyl]-2methyl3-furancarbothiamide), etravirine (TMC125), Trovirdine (Ly300046.HCl), MKC-442 (emivirine, coactinon), HI-236, HI-240, HI-280, HI-281, rilpivirine (TMC-278), MSC-127, HBY 097, DMP266, Baicalin (TJN-151) ADAM-II (Methyl 3′,3′-dichloro-4′,4″-dimethoxy-5′,5″-bis(methoxycarbonyl)-6,6-diphenylhexenoate), Methyl 3-Bromo-5-(1-5-bromo-4-methoxy-3 (methoxycarbonyl)phenyl)hept-1-enyl)-2-methoxybenzoate, 5-chloro-3-(phenylsulfinyl)-2′-indolecarboxamide, U-104489 (PNU-104489), Capravirine (AG-1549, S-1153), atevirdine (U-87201E), aurin tricarboxylic acid (SD-095345), 1-[(6-Cyano-2-indoylyl)carbonyl]-4-[3-(isopropylamino)-2-pyridinyl]piperazine, 1-[5-RN-(methyl)methylsulfonylamino]-2-indolylcarbonyl-4-[3-(isopropylamino)-2-pyridinyl]piperazine, 1-[3-(Ethylamino)-2-[pyridinyl]-4-[(5-hydroxy-2-indolyl)carbonyl]piperazine, 1-[(6-Formyl-2-indoyly)carbonyl]-4-[3-(isopropylamino)-2-pyridinyl]piperazine, 1-[[5-(Methylsulfonyloxy)-2-indoyly)carbonyl]-4-[3-(isopropylamino)-2-pyridinyl]piperazine, U88204E, Bis(2-nitrophenyl)sulfone (NSC 633001), Calanolide A (NSC675451), Calanolide B, 6-Benzyl-5-methyl-2-(cyclohexyloxy)pyrimidin-4-one (DABO-546), DPC 961, E-EBU, E-EBU-dm, E-EPSeU, E-EPU, Foscarnet (Foscavir), HEPT (14(2-Hydroxyethoxy)methyl]-6-(phenylthio)thymine), HEPT-M (1-[(2-Hydroxyethoxy)methyl]-6-(3-methylphenyl)thio)thymine), HEPT-S(1-[(2-Hydroxyethoxy)methyl]-6-(phenylthio)-2-thiothymine), Inophyllum P, L-737,126, Michellamine A (NSC650898), Michellamine B (NSC649324), Michellamine F, 6-(3,5-Dimethylbenzyl)-1-[(2-hydroxyethoxy)methyl]-5-isopropyluracil, 6-(3,5-Dimethylbenzyl)-1-(ethyoxymethyl)-5-isopropyluracil, NPPS, E-BPTU (NSC 648400), Oltipraz (4-Methyl-5-(pyrazinyl)-3H-1,2-dithiole-3-thione), N-{2-(2-Chloro-6-fluorophenethyl]-N′-(2-thiazolyl)thiourea, N-{2-(2,6-Difluorophenethyl]-N′-[2-(5-bromopyridyl)]thiourea, N-{2-(2,6-Difluorophenethyl]-N′-[2-(5-methylpyridyl)]thiourea, N-[2-(3-Fluorofuranyl)ethyl]-N′-[2-(5-chloropyridyl)thiourea, N-[2-(2-Fluoro-6-ethoxyphenethyl)]-N′-[2-(5-bromopyridyl)]thiourea, N-(2-Phenethyl)-N′-(2-thiazolyl)thiourea (LY-73497), L-697,639, L-697,593, L-697,661, 3-[2-(4,7-Difluorobenzoxazol-2-yl)ethyl]-5-ethyl-6-methyl(pypridin-2(1H)-thione, 3-[[(2-Methoxy-5,6-dimethyl-3-pyridyl)methyl]amine]-5-ethyl-6-methyl(pypridin-2(1H)-thione, R82150, R82913, R87232, R88703, R89439 (Loviride), R90385, S-2720, Suramin Sodium, TBZ (Thiazolobenzimidazole, NSC 625487), Thiazoloisoindol-5-one, (+)(R)-9b-(3,5-Dimethylphenyl-2,3-dihydrothiazolo[2,3-a]isoindol-5(9bH)-one, Tivirapine (R86183), UC-38, UC-84 or a mixture thereof.